Risedronic acid
- Generic Name
- Risedronic acid
- Brand Names
- Actonel, Atelvia
- Drug Type
- Small Molecule
- Chemical Formula
- C7H11NO7P2
- CAS Number
- 105462-24-6
- Unique Ingredient Identifier
- KM2Z91756Z
- Background
Risedronic acid is a third generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease. It functions by preventing resorption of bone.
- Indication
Risedronic acid is indicated for the treatment of osteoperosis in men, treatment of Paget's disease, treatment and prevention of osteoperosis in postmenopausal women, and treatment and prevention of glucocorticoid-induced osteoperosis.
- Associated Conditions
- Hypercalcemia of Malignancy, Osteoporosis, Paget’s Disease
- Associated Therapies
- -
Smart Guide to Bone Health
Maintaining bone health is crucial as we age, with osteoporosis posing a significant risk. Key strategies include ensuring adequate calcium and vitamin D intake, engaging in weight-bearing and strength-training exercises, and avoiding smoking and excessive alcohol. Regular bone density tests and medication can also help manage or prevent osteoporosis.
Risedronate prevents exercise-induced hypercalcemia but not nausea or vomit in humans
Exercise-induced gastrointestinal syndrome, hypercalcemia, and bone resorption are reviewed, with implications for health and intestinal disease. Studies show varying effects of exercise on calcium levels, bone structure, and gastrointestinal distress, suggesting a complex interplay between physical activity and physiological responses.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath